NCT02144415 - A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Healthy VolunteersDrug Users

Interventions

DRUG

EB-1020 400 mg

4 x EB-1020 100-mg capsules, and 4 matching placebo capsules

DRUG

EB-1020 800 mg

8 x EB-1020 100-mg capsules

DRUG

lisdexamfetamine 150 mg

3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules

DRUG

d-amphetamine 40 mg

4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules

DRUG

Placebo

8 x matching placebo capsules

Trial Locations (1)

Vince and Associates Clinical Research, Inc., Overland Park